Just compare side effect profile with Jevtana and you can see PSMA ADC has a LOT safer profile
if you are a healthcare provider like i am, take a look at JEVTANA (alternate drug that treats mCRPC)'s package insert and their phase 3 study results. the % of patients developing grade 3/4 neutropenia is A LOT greater than PSMA ADC. Neutropenia is a very common development in chemotherapy, and the fact that it is only 6.7% in 2.3 mg/kg it is VERY LOW for a patient that has METASTATIC CASTRATION-RESISTANT PROSTATE CANCER, meaning LIFE-ENDING DISEASE STAGE. Phase 3 trial will be needed to compared survival rate and I do NOT see why this won't move forward with its nice safety profile.